.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,906,755

« Back to Dashboard

Claims for Patent: 4,906,755

Title: Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
Abstract:The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.
Inventor(s): Gittos; Maurice W. (Plobsheim, FR)
Assignee: Merrell Dow Pharmaceuticals Inc. (Cincinnati, OH)
Application Number:07/376,172
Patent Claims: 1. A compound of the formula: ##STR5## wherein the two lines to both A and B indicate a double bond to a single group or two single bonds to two individual groups as specified; A is (H)(H), .dbd.O, (H)(OH) or .dbd.N--OH; B is (H)(H), (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or .dbd.CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR6## wherein Z is NR.sub.9, O or S; R.sub.5 ; R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, C.sub.1-3 alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl(C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substitutent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quaternary ammonium salts of the aforesaid compounds.

2. A compound according to claim 1 which has the formula: ##STR7## wherein the two lines to both A and B indicate a double bond to a single group or two single bonds to two individual groups as specified; A is (H)(H), .dbd.O, (H)(OH) or .dbd.N--OH; B is (H)(H), (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or .dbd.CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR8## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C-.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, C.sub.1-3 alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl(C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; and the pharmaceutically acceptable acid addition and quaternary ammonium salts of the aforesaid compounds.

3. A compound according to claim 1 which has the formula: ##STR9## wherein the two lines to A indicate a double bond to a single group or two single bonds to two individual groups as specified; A is (H)(H), .dbd.O, (H)(OH) or .dbd.N--OH; R.sub.1 is ##STR10## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, C.sub.1-3 alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl, and the pharmaceutically acceptable acid addition and quaternary ammonium salts of the aforesaid compounds.

4. A compound according to claim 1 which has the formula: ##STR11## wherein R.sub.1 is ##STR12## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, C.sub.1-3 alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl(C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl, and the pharmaceutically acceptable acid addition and quaternary ammonium salts of the aforesaid compounds.

5. A compound according to claim 1 which has the formula: ##STR13## wherein R.sub.1 is ##STR14## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, C.sub.1-3 alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl(C.sub.1-2 alkyl(l R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2, and the pharmaceutically acceptable acid addition and quaternary ammonium salts of the aforesaid compounds.

6. A compound according to claim 1 which is endo-8-(3,5-dimethylbenzoyloxy) hexahydro-2,6-methano-2H-quinolizin-3(4H)-one.

7. A compound according to claim 1 which is endohexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one .

8. A compound according to claim 1 which is endo-hexahydro-8-(1-methyl-3-indazolylcarbonyloxy)-2,6-methano-2H-quinoliz in-3(4H)-one.

9. Endo-Hexahydro-8hydroxy-2,6-methano-2H-quinolizin-3(4H)-one.

10. A compound according to claim 1 which is exo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc